Polyene Phosphatidylcholine

PreclinicalSmall molecule

Polyene Phosphatidylcholine is one of 12 small molecule programs targeting Hyperbilirubinemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperbilirubinemiaActive, not recruiting

HyperbilirubinemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Hyperbilirubinemia

#DrugCompanyPhaseTrials

Verazinc

FFakultas Kedokteran Universitas Indonesia

Phase 2

1 2

Medrol

Pfizer

Preclinical

1 3

Tricor

JJagotec

Preclinical

2 4

Legalon

BBukwang Pharmaceutical

Preclinical

1 5

Reyataz

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 6

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

—7

Glutathione

UUniversity of Chicago

Preclinical

1 8

E. Coli Endotoxin

RRadboud University Medical Center

Preclinical

1 9

Polyene Phosphatidylcholine

AAMIpharm Co., Ltd.

Preclinical

1 10

Bifidobacterium Animalis Subsp. Lactis

UUniversity of Sao Paulo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Not yet recruiting

Hematological Diseases

NCT07476885

Q3 2027

N/ARecruiting

Hyperbilirubinemia

NCT06922669

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area

Completed·AAMIpharm Co., Ltd.·Phase 3·NCT06256445·252 enrolled

Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat

Completed·AAMIpharm Co., Ltd.·Phase 2·NCT03982225·143 enrolled

Hematological Diseases1 trial

A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China··NCT07476885·1,000 enrolled

Hyperbilirubinemia1 trial

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT06922669·232 enrolled

Double-blind1 trial

The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI

Completed·DDrug Induced Liver Disease Study Group·Phase 2·NCT02944552·244 enrolled

Unspecified2 trials

Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects

Completed·AAMIpharm Co., Ltd.·Phase 1·NCT05476094·26 enrolled

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

Completed·AAMIpharm Co., Ltd.·Phase 2·NCT05266729·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Polyene Phosphatidylcholine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polyene Phosphatidylcholine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Polyene Phosphatidylcholine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AMIpharm Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAMIpharm Co., Ltd.

Polyene Phosphatidylcholine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Efficacy and Safety2 trials

Hematological Diseases1 trial

Hyperbilirubinemia1 trial

Double-blind1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News